This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. Names of those capital sources were not announced.
Pasadena-based venturecapital firm ArcturusCapital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. Arcturus first invested in Pliant in 2007. SanDisk is a major manufacturer of flash memory.
San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venturecapital rnai lifescience biotech' and Canada.
San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds.
Los Angeles-based Arcturus, a developer of 3D video editing tools, said Wednesday afternoon that it has raised $11M in a Series A funding round. The funding was led by Cloudtree Ventures, and also included Autodesk and Epic Games. The startup is led by CEO Kamal Mistry.
TrueCar is venture backed by backed by USAA, Capricorn Investment Group, Upfront Ventures, Anthem Ventures, Vulcan Capital Growth Equity, Peppy Capital Partners, ArcturusVentureCapital, along with others. TrueCar is trading on the NASDAQ Global Select Market as TRUE. READ MORE>>.
Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. Tags: sorrento therapeutics biotech venturecapital lifescience aviaradx. The firm is headed by Antonius Schuh, who serves as founding chairman and CEO; the firm's CFO is Steve Zaniboni.
The round was led by Prospector Equity Capital and ArcturusCapital, and also included the Pasadena Angels and Tech Coast Angels. Monrovia-based Ondax , a manufacturer of volume holographic grating filters and lasers, said Tuesday that it has officially closed its $2.2M, Series E funding round.
Zag has previously received venturecapital from such firms as Anthem Ventures, GRP Partners, the Tech Coast Angels, Capricorn Management, Capital One, and ArcturusCapital. The firm did not say what drove the growth, and did not provide any financial details on its sales or profitability.
The money came from a wide range of backers, not just traditional biotech venture firms. billion, a figure compiled in the Venture Monitor Report. Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days.
The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. But the results, touted as positive, left more questions than answers.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content